Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
复制标题
DOI：
10.1186/bcr2225
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
Anton-Culver H
中科院分区：
文献类型：
--
作者：
Zell JA;Tsang WY;Taylor TH;Mehta RS;Anton-Culver H
炎症性乳腺癌(IBC)是一种侵袭性乳腺癌，与Her2/Neu(人表皮生长因子样受体2(HER2))的过度表达和低生存率相关。我们使用加州癌症登记处的数据，以局部晚期乳腺癌(LABC)、转移性乳腺癌(MBC)和非T4乳腺癌为对照，研究了IBC患者基于激素受体状态和HER2受体状态的存活率差异。对加州癌症登记处1999年至2003年期间发生的80,099例女性乳腺癌患者进行了仅病例分析，并进行了跟踪调查，直至2007年3月。采用Kaplan-Meier方法和Cox比例风险比分析总生存率(OS)和乳腺癌特异性生存率(BC-SS)。总共确定了2,014例IBC，1,268例LABC，3,059 MBC和73,758例非T4乳腺癌患者。HER2+与晚期肿瘤分期相关(P<；0.0001)。与LABC(35%和69%)、MBC(35%和74%)和非T4患者(22%和82%)相比，IBC患者HER2+的可能性更大(40%)，激素受体阳性(HMR+)的可能性较小(59%)。在调整了临床相关因素后，HMR+状态与每个乳腺癌亚型的OS和BC-SS改善相关。在多变量分析中，HER2+(相对于HER2-)状态与非T4患者较差的BC-SS有关(危险比=1.16，95%可信区间1.05~1.28)，与IBC改善的BC-SS有关(危险比=0.82，95%可信区间=0.68~0.99)。尽管HER2+与晚期肿瘤分期有关，但HER2+状态并不是影响IBC患者生存的独立不良预后因素。
Inflammatory breast cancer (IBC) is an aggressive form of breast cancer associated with overexpression of Her2/Neu (human epidermal growth factor-like receptor 2 (HER2)) and poor survival. We investigated survival differences for IBC patient cases based on hormone receptor status and HER2 receptor status using data from the California Cancer Registry, as contrasted with locally advanced breast cancer (LABC), metastatic breast cancer (MBC) and non-T4 breast cancer. A case-only analysis of 80,099 incident female breast cancer patient cases in the California Cancer Registry during 1999 to 2003 was performed, with follow-up through March 2007. Overall survival (OS) and breast cancer-specific survival (BC-SS) were analyzed using Kaplan–Meier methods and Cox proportional hazards ratios. A total of 2,014 IBC, 1,268 LABC, 3,059 MBC, and 73,758 non-T4 breast cancer patient cases were identified. HER2+ was associated with advanced tumor stage (P < 0.0001). IBC patient cases were more likely to be HER2+ (40%) and less likely to be hormone receptor-positive (HmR+) (59%) compared with LABC (35% and 69%, respectively), MBC (35% and 74%), and non-T4 patient cases (22% and 82%). HmR+ status was associated with improved OS and BC-SS for each breast cancer subtype after adjustment for clinically relevant factors. In multivariate analysis, HER2+ (versus HER2-) status was associated with poor BC-SS for non-T4 patient cases (hazards ratio = 1.16, 95% confidence interval 1.05 to 1.28) and had a borderline significant association with improved BC-SS for IBC (hazards ratio = 0.82, 95% confidence interval = 0.68 to 0.99). Despite an association with advanced tumor stage, HER2+ status is not an independent adverse prognostic factor for survival among IBC patient cases.
登录
查看更多内容
影响因子：
50.5
作者：
Gluz, O.;Nitz, U. A.;Mohrmann, S.
通讯作者：
Mohrmann, S.
影响因子：
10.3
作者：
Hance, KW;Anderson, WF;Levine, PH
通讯作者：
Levine, PH
影响因子：
6.2
作者：
Ou, S. -H. Ignatius;Zell, Jason A.;Anton-Culver, Hoda
通讯作者：
Anton-Culver, Hoda
影响因子：
3.9
作者：
Parton, M;Dowsett, M;Smith, IE
通讯作者：
Smith, IE
影响因子：
120.7
作者：
Berry, DA;Cirrincione, C;Winer, EP
通讯作者：
Winer, EP